ArticleResuscitation2023
Kidney-specific biomarkers for predicting acute kidney injury following cardiac arrest.
Article in Resuscitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Kidney injury molecule 1 in the early detection of acute kidney injury-a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- A multimodal predictive model incorporating transcriptomic-guided blood biomarkers and clinical variables for sepsis-associated acute kidney injury.Renal failure · 2026Article
- Association between C-reactive protein-to-platelet ratio and acute kidney injury in cardiac arrest survivors.BMC cardiovascular disorders · 2026Article
- Effects of tocilizumab on neutrophil gelatinase-associated lipocalin following out-of-hospital cardiac arrest, and its prognostic value.Resuscitation plus · 2026Article
- Critical care considerations in rhabdomyolysis-associated acute kidney injury and kidney replacement therapy.World journal of nephrology · 2026Review
- Intravoxel incoherent motion MRI for early detection and assessment of renal injury after cardiac arrest and resuscitation in a rat model.European radiology experimental · 2026Article
- Development of a Clinical Prediction Model for Acute Kidney Injury Among In-Hospital Cardiac Arrest Patients During Intensive Care Unit Hospitalization.Reviews in cardiovascular medicine · 2026Article
- Dual-phase CT radiomics for acute kidney injury prediction after out-of-hospital cardiac arrest.Frontiers in radiology · 2026Article
- Proteomics identify pathogenesis and novel biomarkers for monitoring and early prognostication of brain injury after cardiac arrest: a randomized animal study.Resuscitation plus · 2025Article
- Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.Current heart failure reports · 2025Review
- Exploring Biomarkers for Malaria: Advances in Early Detection and Asymptomatic Diagnosis.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
aimTo evaluate the performance of kidney-specific biomarkers (neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and cystatin-C) in early detection of acute kidney injury (AKI) following cardiac arrest (CA) when compared to serum creatinine.
methodsAdult CA patients who had kidney-specific biomarkers of AKI collected within 12 h of return of spontaneous circulation (ROSC) were included. The association between renal biomarker levels post-ROSC and the development of KDIGO stage III AKI within 7 days of enrollment were assessed as well as their predictive value of future AKI development, neurological outcomes, and survival to discharge.
resultsOf 153 patients, 54 (35%) developed stage III AKI within 7 days, and 98 (64%) died prior to hospital discharge. Patients who developed stage III AKI, compared to those who did not, had higher median levels of creatinine, NGAL, and cystatin-C (p < 0.001 for all). There was no statistically significant difference in KIM-1 between groups. No biomarker outperformed creatinine in the ability to predict stage III AKI, neurological outcomes, or survival outcomes (p > 0.05 for all). However, NGAL, cystatin-C, and creatinine all performed better than KIM-1 in their ability to predict AKI development (p < 0.01 for all).
conclusionIn post-CA patients, creatinine, NGAL, and cystatin-C (but not KIM-1) measured shortly after ROSC were higher in patients who subsequently developed AKI. No biomarker was statistically superior to creatinine on its own for predicting the development of post-arrest AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.